Phosphopeptides as melanoma vaccines
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4 + T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4 + T cells are potential targets for cancer immunotherapy.
1. A composition comprising: an isolated phosphopeptide consisting of between 9 and 30 contiguous amino acids selected from SEQ ID NO:1 (MART-1) including motif YEKLSA (residues 104-109 of SEQ ID NO: 1) containing the serine at position 108 of MART-1, wherein the serine is phosphorylated, wherein the phosphopeptide binds to HLA-DR1; and
an effective amount of an immune adjuvant.
2. The composition of claim 1 , which is substantially free of other polypeptides.
3. The composition of claim 1 , which is substantially free of human cells.
4. The composition of claim 1 , wherein the phosphopeptide is in a complex with an HLADR1 molecule.
5. The composition of claim 4 wherein the complex is a tetramer.
6. The composition of claim 3 which comprises an admixture with one or more distinct phosphopeptides.
7. The composition of claim 6 wherein the one or more distinct phosphopeptides are melanoma-specific.
8. The composition of claim 4 wherein the HLA-DR1 molecule is HLA-DRB1*0101.
9. The composition of claim 1 wherein the isolated phosphopeptide consists of an amino acid sequence selected from the group consisting of: residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), residues 100-115 (SEQ ID NO: 16), and residues 100-116 (SEQ ID NO: 17).
10. The composition of claim 5 which comprises a specific reagent to bring monomers or dimers together as a tetramer.
11. The composition of claim 5 which comprises biotin as a specific reagent to bring monomers or dimers together as a tetramer.
12. The composition of claim 5 which comprises (a) biotin and avidin or (b) biotin and streptavidin as specific reagents to bring monomer or dimers together as a tetramer.
13. The composition of claim 1 wherein the phosphopeptide consists of the amino acid sequence of SEQ ID NO: 14.
14. The composition of claim 8 wherein the complex is a tetramer.
15. A composition comprising: an isolated phosphopeptide consisting of between 9 and 30 contiguous amino acids selected from SEQ ID NO:1 (MART-1) including motif YEKLSA (residues 104-109 of SEQ ID NO: 1) containing the serine at position 108 of MART-1, wherein the serine is phosphorylated, wherein the phosphopeptide binds to HLA-DR1, and wherein the phosphopeptide is detectably labeled.
16. A composition comprising: an isolated phosphopeptide consisting of between 9 and 30 contiguous amino acids selected from SEQ ID NO:1 (MART-1) including motif YEKLSA (residues 104-109 of SEQ ID NO: 1) containing the serine at position 108 of MART-1, wherein the serine is phosphorylated, wherein the phosphopeptide binds to HLA-DR1, and wherein the phosphopeptide is bound to a solid support.
17. A composition comprising: an isolated phosphopeptide consisting of between 9 and 30 contiguous amino acids selected from SEQ ID NO:1 (MART-1) containing the serine at position 108 of MART-1, wherein the serine is phosphorylated, wherein the phosphopeptide binds to HLA-DR1, said phosphopeptide selected from the group consisting of residues 101-109 (SEQ ID NO:3), residues 102-110 (SEQ ID NO:4), residues 103-111 (SEQ ID NO: 5), residues 104-112 (SEQ ID NO: 6), residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), residues 100-115 (SEQ ID NO: 16), and residues 100-116 (SEQ ID NO: 17); and
an effective amount of an adjuvant.
18. The composition of claim 1 wherein the isolated phosphopeptide consists of an amino acid sequence selected from the group consisting of: residues 101-109 (SEQ ID NO:3), residues 102-110 (SEQ ID NO:4), residues 103-111 (SEQ ID NO: 5), residues 104-112 (SEQ ID NO: 6), residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), and residues 100-115 (SEQ ID NO: 16).
19. The composition of claim 15 wherein the isolated phosphopeptide consists of an amino acid sequence selected from the group consisting of residues 101-109 (SEQ ID NO:3), residues 102-110 (SEQ ID NO:4), residues 103-111 (SEQ ID NO: 5), residues 104-112 (SEQ ID NO: 6), residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), and residues 100-115 (SEQ ID NO: 16).
20. The composition of claim 16 wherein the isolated phosphopeptide consists of an amino acid sequence selected from the group consisting of residues 101-109 (SEQ ID NO:3), residues 102-110 (SEQ ID NO:4), residues 103-111 (SEQ ID NO: 5), residues 104-112 (SEQ ID NO: 6), residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), and residues 100-115 (SEQ ID NO: 16.
21. The composition of claim 17 wherein the isolated phosphopeptide consists of an amino acid sequence selected from the group consisting of residues 101-109 (SEQ ID NO:3), residues 102-110 (SEQ ID NO:4), residues 103-111 (SEQ ID NO: 5), residues 104-112 (SEQ ID NO: 6), residues 97-116 (SEQ ID NO: 11), residues 99-110 (SEQ ID NO: 13), residues 100-111 (SEQ ID NO: 14), residues 100-114 (SEQ ID NO: 15), and residues 100-115 (SEQ ID NO: 16).